References
- Smith CR, Leon MB, Mack MJ, et al. Transcatheter versus surgical aortic-valve replacement in high-risk patients. N Engl J Med [Internet]. 2011 [cited 2018 Apr 21];364:2187–2198. Available from: http://www.nejm.org/doi/abs/10.1056/NEJMoa1103510
- Adams DH, Popma JJ, Reardon MJ, et al. Transcatheter aortic-valve replacement with a self-expanding prosthesis. N Engl J Med [Internet]. 2014 [cited 2018 Apr 21];370:1790–1798. Available from: http://www.nejm.org/doi/10.1056/NEJMoa1400590
- Leon MB, Smith CR, Mack MJ, et al. Transcatheter or surgical aortic-valve replacement in intermediate-risk patients. N Engl J Med [Internet]. 2016 [cited 2018 Apr 21];374:1609–1620. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27040324
- Reardon MJ, Van Mieghem NM, Popma JJ, et al. Surgical or transcatheter aortic-valve replacement in intermediate-risk patients. N Engl J Med [Internet]. 2017 [cited 2018 Apr 21];376:1321–1331. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28304219
- Baumgartner H, Falk V, Bax JJ, et al. ESC/EACTS guidelines for the management of valvular heart disease. Eur Heart J. 2017;38:2739–2791.
- Möllmann H, Diemert P, Grube E, et al. Symetis ACURATE TFTM aortic bioprosthesis. EuroIntervention. 2013;9:S107–S110.
- Perlman G, Cheung A, Dumont E, et al. Transcatheter aortic valve replacement with the Portico valve: one-year results of the early Canadian experience. EuroIntervention [Internet]. 2017;12:1653–1659. Available from: http://www.pcronline.com/eurointervention/110th_issue/271
- Meredith IT, Hood KL, Haratani N, et al. Boston scientific lotus valve. EuroIntervention [Internet]. 2012;8:Q70-Q74. Available from: https://www.pcronline.com/eurointervention/Q_issue/12
- Vendrik J, van Kesteren F, van Mourik MS, et al. Procedural outcome and midterm survival of lower risk transfemoral transcatheter aortic valve implantation patients treated with the SAPIEN XT or SAPIEN 3 device. Am J Cardiol. 2018;121:856–861.
- Wendler O, Schymik G, Treede H, et al. SOURCE 3: 1-year outcomes post-transcatheter aortic valve implantation using the latest generation of the balloon-expandable transcatheter heart valve. Eur Heart J. 2017;38:2717–2726.
- Romano M, Frank D, Cocchieri R, et al. Transaortic transcatheter aortic valve implantation using SAPIEN XT or SAPIEN 3 valves in the ROUTE registry. Interact Cardiovasc Thorac Surg. 2017;25:757–764.
- Kodali S, Thourani VH, White J, et al. Early clinical and echocardiographic outcomes after SAPIEN 3 transcatheter aortic valve replacement in inoperable, high-risk and intermediate-risk patients with aortic stenosis. Eur Heart J. 2016;37:2252–2262.
- Wöhrle J, Gonska B, Rodewald C, et al. Transfemoral aortic valve implantation with the new edwards sapien 3 valve for treatment of severe aortic stenosis - Impact of valve size in a single center experience. PLoS One [Internet]. 2016;11:1–10.
- Vahanian A, Urena M, Walther T, et al. Thirty-day outcomes in patients at intermediate risk for surgery from the SAPIEN 3 European approval trial. EuroIntervention. 2016;12:e235–e243.
- Webb J, Gerosa G, Lefèvre T, et al. Multicenter evaluation of a next-generation balloon-expandable transcatheter aortic valve. J Am Coll Cardiol [Internet]. 2014;64:2235–2243.
- Wendler O, Schymik G, Treede H, et al. SOURCE 3 registry: design and 30-day results of the European postapproval registry of the latest generation of the sapien 3 transcatheter heart valve. Circulation. 2017;135:1123–1132.
- Thourani VH, Kodali S, Makkar RR, et al. Transcatheter aortic valve replacement versus surgical valve replacement in intermediate-risk patients: a propensity score analysis. Lancet [Internet]. 2016 [cited 2018 Apr 21];387:2218–2225. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27053442
- Ando T, Briasoulis A, Holmes AA, et al. Sapien 3 versus Sapien XT prosthetic valves in transcatheter aortic valve implantation: a meta-analysis. Int J Cardiol [Internet]. 2016 [cited 2018 Apr 21];220:472–478. Available from: http://linkinghub.elsevier.com/retrieve/pii/S016752731631169X
- Ferrari E, Caporali E, Pedrazzini G, et al. Trans-carotid access for TAVR allows safe and rapid exchange for bailout valve-in-valve procedures. J Card Surg [Internet]. 2018 [cited 2018 Sep 17];33:4–6. Available from: http://doi.wiley.com/10.1111/jocs.13513
- Bruschi G, Merlanti B, Colombo P, et al. Evolut R implantation via the brachial artery. Eur J Cardiothorac Surg [Internet]. 2018 [cited 2018 Sep 17]; Available from: https://academic.oup.com/ejcts/advance-article/doi/10.1093/ejcts/ezy201/5033012
- Bruschi G, De Marco F, Modine T, et al. Alternative transarterial access for CoreValve transcatheter aortic bioprosthesis implantation. Expert Rev Med Devices [Internet]. 2015 [cited 2018 Sep 17];12:279–286. Available from: http://www.tandfonline.com/doi/full/10.1586/17434440.2015.1005605
- Forrest JK, Mangi AA, Popma JJ, et al. Early outcomes with the evolut PRO repositionable self-expanding transcatheter aortic valve with pericardial wrap. JACC Cardiovasc Interv. 2018;11:181–191.
- Grube E, Van Mieghem NM, Bleiziffer S, et al. Clinical outcomes with a repositionable self-expanding transcatheter aortic valve prosthesis: the international FORWARD study. J Am Coll Cardiol. 2017;70:845–853.
- Sorajja P, Kodali S, Reardon MJ, et al. Outcomes for the commercial use of self-expanding prostheses in transcatheter aortic valve replacement: a report from the STS/ACC TVT registry. JACC Cardiovasc Interv. 2017;10:2090–2098.
- Kalra SS, Firoozi S, Yeh J, et al. Initial experience of a second-generation self-expanding transcatheter aortic valve: the UK & Ireland evolut R implanters’ registry. JACC Cardiovasc Interv. 2017;10:276–282.
- Popma JJ, Reardon MJ, Khabbaz K, et al. Early clinical outcomes after transcatheter aortic valve replacement using a novel self-expanding bioprosthesis in patients with severe aortic stenosis who are suboptimal for surgery: results of the evolut R U.S. study. JACC Cardiovasc Interv. 2017;10:268–275.
- Noble S, Stortecky S, Heg D, et al. Comparison of procedural and clinical outcomes with evolut R versus medtronic corevalve: a Swiss TAVI registry analysis. EuroIntervention. 2017;12:e2170–e2176.
- Gomes B, Geis NA, Chorianopoulos E, et al. Improvements of procedural results with a new-generation self-expanding transfemoral aortic valve prosthesis in comparison to the old-generation device. J Interv Cardiol. 2017;30:72–78.
- Giannini C, De Carlo M, Tamburino C, et al. Transcathether aortic valve implantation with the new repositionable self-expandable evolut R versus coreValve system: a case-matched comparison. Int J Cardiol. 2017;243:126–131.
- Ben-Shoshan J, Konigstein M, Zahler D, et al. Comparison of the Edwards SAPIEN S3 versus medtronic evolut-R devices for transcatheter aortic valve implantation. Am J Cardiol. 2017;119:302–307.
- Thiele H A 2×2 ramdonized trial of self-expandable vs balloon-expandable valves and general vs local anesthesia in patients undergoing transcatheter aortic valve implantation. Pap. Present. Transcatheter Cardiovasc. Ther. Meet. Sept 21-25, 2018; San Diego, CA.
- Möllmann H, Hengstenberg C, Hilker M, et al. Real-world experience using the ACURATE neo prosthesis: 30-day outcomes of 1,000 patients enrolled in the SAVI TF registry. EuroIntervention [Internet]. 2018 [cited 2018 Mar 19];13:e1764–e1770. Available from: http://www.pcronline.com/eurointervention/130th_issue/286
- Pellegrini C, Husser O, Kim W-K, et al. Predictors of need for permanent pacemaker implantation and conduction abnormalities with a novel self-expanding transcatheter heart valve. Rev Esp Cardiol. English Ed [Internet]. 2018 [cited 2018 Apr 21]; Available from: http://linkinghub.elsevier.com/retrieve/pii/S1885585718300392
- Toggweiler S, Nissen H, Mogensen B, et al. Very low pacemaker rate following ACURATE neo transcatheter heart valve implantation. EuroIntervention [Internet]. 2017 [cited 2018 Mar 19];13:1273–1280. Available from: http://www.pcronline.com/eurointervention/126th_issue/202
- Börgermann J, Holzhey DM, Thielmann M, et al. Transcatheter aortic valve implantation using the ACURATE TATM system: 1-year outcomes and comparison of 500 patients from the SAVI registries. Eur J Cardio-Thorac Surg [Internet]. 2017;51:936–942. Available from: https://academic.oup.com/ejcts/article-lookup/doi/10.1093/ejcts/ezw423
- Hamm K, Reents W, Zacher M, et al. Transcatheter aortic valve implantation using the ACURATE TA and ACURATE neo valves: a 4-year single-center experience. EuroIntervention J Eur Collab with Work Gr Interv Cardiol Eur Soc Cardiol. 2017;13(1):53–59.
- Kempfert J, Holzhey D, Hofmann S, et al. First registry results from the newly approved ACURATE TA??? TAVI system. Eur J Cardiothorac Surg. 2015;48:137–141.
- Husser O, Kim W-K, Pellegrini C, et al. Multicenter comparison of novel self-expanding versus balloon-expandable transcatheter heart valves. JACC Cardiovasc Interv [Internet]. 2017 [cited 2018 Mar 19];10:2078–2087. Available from: http://linkinghub.elsevier.com/retrieve/pii/S193687981731258X
- Möllmann H, Linke A, Holzhey DM, et al. Implantation and 30-day follow-up on all 4 valve sizes within the portico transcatheter aortic bioprosthetic family. JACC Cardiovasc Interv. 2017;10:1538–1547.
- Mas-Peiro S, Vasa-Nicotera M, Weiler H, et al. Thirty-day outcomes in 100 consecutive patients undergoing transfemoral aortic valve replacement with the portico valve on an all-comer basis. J Invasive Cardiol [Internet]. 2017 [cited 2018 Apr 21];29:431–436. Available from: http://www.ncbi.nlm.nih.gov/pubmed/29207365
- Manoharan G, Linke A, Moellmann H, et al. Multicentre clinical study evaluating a novel resheathable annular functioning self-expanding transcatheter aortic valve system: safety and performance results at 30 days with the Portico system. EuroIntervention. 2016;12:768–774.
- Reichenspurner H, Schaefer A, Schäfer U, et al. Self-expanding transcatheter aortic valve system for symptomatic high-risk patients with severe aortic stenosis. J Am Coll Cardiol [Internet]. 2017 [cited 2018 Mar 20];70:3127–3136. Available from: http://linkinghub.elsevier.com/retrieve/pii/S073510971741360X
- Doshi SN, George S, Kwok CS, et al. A feasibility study of transaxillary TAVI with the lotus valve. Catheter Cardiovasc Interv [Internet]. 2018 [cited 2018 Nov 6];92:542–549. Available from: http://doi.wiley.com/10.1002/ccd.27409
- Damluji AA, Murman M, Byun S, et al. Alternative access for transcatheter aortic valve replacement in older adults: a collaborative study from France and United States. Catheter Cardiovasc Interv [Internet]. 2018 [cited 2018 Nov 6]; Available from: http://doi.wiley.com/10.1002/ccd.27690
- Falk V, Wöhrle J, Hildick-Smith D, et al. Safety and efficacy of a repositionable and fully retrievable aortic valve used in routine clinical practice: the RESPOND study. Eur Heart J. 2017;38:3359–3366.
- Montone RA, Testa L, Fraccaro C, et al. Procedural and 30-day clinical outcomes following transcatheter aortic valve replacement with lotus valve: results of the RELEVANT study. Catheter Cardiovasc Interv. 2017;90:1206–1211.
- Meredith IT, Dumonteil N, Blackman DJ, et al. Repositionable percutaneous aortic valve implantation with the LOTUS valve: 30-day and 1-year outcomes in 250 highrisk surgical patients. EuroIntervention. 2017;13:788–795.
- Rampat R, Khawaja MZ, Byrne J, et al. Transcatheter aortic valve replacement using the repositionable LOTUS valve: United Kingdom experience. JACC Cardiovasc Interv. 2016;9:367–372.
- De Backer O, Götberg M, Ihlberg L, et al. Efficacy and safety of the Lotus valve system for treatment of patients with severe aortic valve stenosis and intermediate surgical risk: results from the nordic Lotus-TAVR registry. Int J Cardiol. 2016;219:92–97.
- Wöhrle J, Gonska B, Rodewald C, et al. Transfemoral aortic valve implantation with the repositionable Lotus valve for treatment of patients with symptomatic severe aortic stenosis: results from a single-centre experience. EuroIntervention [Internet]. 2016 [cited 2018 Apr 21];12:760–767. Available from: http://www.pcronline.com/eurointervention/103rd_issue/124
- Meredith IT, Worthley SG, Whitbourn RJ, et al. Transfemoral aortic valve replacement with the repositionable Lotus valve system in high surgical risk patients: the REPRISE I study. EuroIntervention [Internet]. 2014 [cited 2018 Apr 21];9:1264–1270. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24169077
- Meredith Am IT, Walters DL, Dumonteil N, et al. Transcatheter aortic valve replacement for severe symptomatic aortic stenosis using a repositionable valve system: 30-day primary endpoint results from the REPRISE II study. J Am Coll Cardiol. 2014;64:1339–1348.
- van Rosendael PJ, Delgado V, Bax JJ. Pacemaker implantation rate after transcatheter aortic valve implantation with early and new-generation devices: a systematic review. Eur Heart J [Internet]. 2018;1–14. Available from: https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehx785/4840597
- Siontis GCM, Jüni P, Pilgrim T, et al. Predictors of permanent pacemaker implantation in patients with severe aortic stenosis undergoing TAVR: a meta-analysis. J Am Coll Cardiol. 2014;64:129–140.
- Pilgrim T, Stortecky S, Nietlispach F, et al. Repositionable versus balloon-expandable devices for transcatheter aortic valve implantation in patients with aortic stenosis. J Am Heart Assoc. 2016; 5.
- Feldman TE, Reardon MJ, Rajagopal V, et al. Effect of mechanically expanded vs self-expanding transcatheter aortic valve replacement on mortality and major adverse clinical events in high-risk patients with aortic stenosis. JAMA [Internet]. 2018;319:27. Available from: http://jama.jamanetwork.com/article.aspx?doi=10.1001/jama.2017.19132
- US Securities and Exchange Commission. Product announcement: Boston scientific, Lotus Valve devices. 2017.
- Auffret V, Lefevre T, Van Belle E, et al. Temporal trends in transcatheter aortic valve replacement in France: FRANCE 2 to FRANCE TAVI. J Am Coll Cardiol. 2017;70:42–55.
- Husser O, Fujita B, Hengstenberg C, et al. Conscious sedation versus general anesthesia in transcatheter aortic valve replacement. JACC Cardiovasc Interv. [Internet]. 2018;11:567–578. Available from: http://linkinghub.elsevier.com/retrieve/pii/S1936879818303492
- Hyman MC, Vemulapalli S, Szeto WY, et al. Conscious sedation versus general anesthesia for transcatheter aortic valve replacement: insightsfrom the national cardiovascular data registry society of thoracic surgeons/American college of cardiology transcatheter valve therapy registry. Circulation. 2017;136:2132–2140.
- Popma JJ, Adams DH, Reardon MJ, et al. Transcatheter aortic valve replacement using a self-expanding bioprosthesis in patients with severe aortic stenosis at extreme risk for surgery. J Am Coll Cardiol [Internet]. 2014 [cited 2018 Sep 18];63:1972–1981. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24657695
- Généreux P, Webb JG, Svensson LG, et al. Vascular complications after transcatheter aortic valve replacement. J Am Coll Cardiol [Internet]. 2012 [cited 2018 Sep 18];60:1043–1052. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22883632
- Auffret V, Regueiro A, Del Trigo M, et al. Predictors of early cerebrovascular events in patients with aortic stenosis undergoing transcatheter aortic valve replacement. J Am Coll Cardiol. 2016;68:673–684.
- Hui S, Gooley R, Rashid HN, et al. Transcatheter aortic valve replacement and atrial fibrillation: impact of antithrombotic strategy on clinical outcomes. Heart Lung Circ. Internet. 2018;1–6. doi:10.1016/j.hlc.2018.03.021
- Abdul-Jawad Altisent O, Durand E, Muñoz-García AJ, et al. Warfarin and antiplatelet therapy versus warfarin alone for treating patients with atrial fibrillation undergoing transcatheter aortic valve replacement. JACC Cardiovasc Interv [Internet]. 2016;9:1706–1717. Available from.
- Rodés-Cabau J, Masson JB, Welsh RC, et al. Aspirin versus aspirin plus clopidogrel as antithrombotic treatment following transcatheter aortic valve replacement with a balloon-expandable valve: the ARTE (Aspirin Versus Aspirin + Clopidogrel following transcatheter aortic valve implantation) randomi. JACC Cardiovasc Interv. 2017;10:1357–1365.
- Seeger J, Gonska B, Otto M, et al. Cerebral embolic protection during transcatheter aortic valve replacement significantly reduces death and stroke compared with unprotected procedures. JACC Cardiovasc Interv [Internet]. 2017 [cited 2018 Nov 10];10:2297–2303. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28917515
- Urena M, Mok M, Serra V, et al. Predictive factors and long-term clinical consequences of persistent left bundle branch block following transcatheter aortic valve implantation with a balloon-expandable valve. J Am Coll Cardiol [Internet]. 2012 [cited 2018 Nov 10];60:1743–1752. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0735109712030409
- van der Boon RMA, Houthuizen P, Urena M, et al. Trends in the occurrence of new conduction abnormalities after transcatheter aortic valve implantation. Catheter Cardiovasc Interv [Internet]. 2015 [cited 2018 Nov 10];85:E144–E152. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25504891
- Walther T, Manoharan G, Linke A, et al. Incidence of new-onset left bundle branch block and predictors of new permanent pacemaker following transcatheter aortic valve replacement with the PorticoTM valve†. Eur J Cardio-Thorac Surg [Internet]. 2018;1–8. Available from: https://academic.oup.com/ejcts/advance-article/doi/10.1093/ejcts/ezy078/4925524
- Roy DA, Schaefer U, Guetta V, et al. Transcatheter aortic valve implantation for pure severe native aortic valve regurgitation. J Am Coll Cardiol. 2013;61:1577–1584.
- Franzone A, Piccolo R, Siontis GCM, et al. Transcatheter aortic valve replacement for the treatment of pure native aortic valve regurgitation: a systematic review. JACC Cardiovasc Interv [Internet]. 2016;9:2308–2317.
- Urena M, Himbert D, Ohlmann P, et al. Transcatheter aortic valve replacement to treat pure aortic regurgitation on noncalcified native valves. J Am Coll Cardiol [Internet]. 2016;68:1705–1706. Available from.
- Dvir D, Webb JG, Bleiziffer S, et al. Transcatheter aortic valve implantation in failed bioprosthetic surgical valves. JAMA. 2014;312:162–170.
- Paradis JM, Del Trigo M, Puri R, et al. Transcatheter valve-in-valve and valve-in-ring for treating aortic and mitral surgical prosthetic dysfunction. J Am Coll Cardiol. 2015;66:2019–2037.
- Neupane S, Singh H, Lämmer J, et al. Meta-analysis of transcatheter valve-in-valve implantation versus redo aortic valve surgery for bioprosthetic aortic valve dysfunction. Am J Cardiol [Internet]. 2018;121:1593–1600. Available from: http://linkinghub.elsevier.com/retrieve/pii/S000291491830290X%0Ahttp://www.ncbi.nlm.nih.gov/pubmed/29776652
- Perlman GY, Blanke P, Dvir D, et al. Bicuspid aortic valve stenosis: favorable early outcomes with a next-generation transcatheter heart valve in a multicenter study. JACC Cardiovasc Interv [Internet]. 2016;9:817–824.
- Yoon SH, Lefèvre T, Ahn JM, et al. Transcatheter aortic valve replacement with early- and new-generation devices in bicuspid aortic valve stenosis. J Am Coll Cardiol [Internet]. 2016;68:1195–1205. Available from.
- Reddy G, Wang Z, Nishimura RA, et al. Transcatheter aortic valve replacement for stenotic bicuspid aortic valves: systematic review and meta analyses of observational studies. Catheter Cardiovasc Interv. 2017;91(5):1–9.
- Salaun E, Clavel M-A, Rodés-Cabau J, et al. Bioprosthetic aortic valve durability in the era of transcatheter aortic valve implantation. Heart [Internet]. 2018 [cited 2018 Sep 18];104:1323–1332. Available from: http://heart.bmj.com/lookup/doi/10.1136/heartjnl-2017-311582
- Arsalan M, Walther T. Durability of prostheses for transcatheter aortic valve implantation. Nat Rev Cardiol [Internet]. 2016 [cited 2018 Sep 18];13:360–367. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27053461